Exatecan Intermediate 5

Cat. No.:	HY-43564				
CAS No.:	143655-70-3				
Molecular Formula:	C ₁₅ H ₁₇ FN ₂ O ₃				
Molecular Weight:	292.31				
Target:	ADC Cytotoxin; Topoisomerase				
Pathway:	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg			
	Preparing Stock Solutions	1 mM	3.4210 mL	17.1051 mL	34.2103 mL			
		5 mM	0.6842 mL	3.4210 mL	6.8421 mL			
		10 mM	0.3421 mL	1.7105 mL	3.4210 mL			
	Please refer to the so	lubility information to select the ap	propriate solvent.					
n Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.2 mg/mL (7.53 mM); Suspended solution; Need ultrasonic						
Solubility: 3. Add each s		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.2 mg/mL (7.53 mM); Clear solution						
		each solvent one by one: 10% DMSO >> 90% corn oil bility:≥2.2 mg/mL (7.53 mM); Clear solution						

BIOLOGICAL ACTIVITY						
Description	Exatecan Intermediate 5 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 5 can be used to synthesize Antibody-Drug Conjugates (ADCs).					
IC ₅₀ & Target	Camptothecins					



Product Data Sheet

REFERENCES

[1]. Xu, et al. Preparation of exatecan intermediate and its application. China, CN115701419 A. 2023-02-10.

[2]. Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86(8):776-82.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA